Deutsche Bank analyst Dan Leonard raised his price target for Illumina to $330 saying the “strong beat” in Q2 on stronger NovaSeq demand supports his thesis. The analyst sees upside for estimates over the next 6-12 months and reiterates a Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.